SUMMARY

OncologySTAT Editorial Team

In the treatment of advanced colorectal cancer (ACC), there is a growing need for early predictive markers of response to therapy, including therapy using targeted agents, to avoid unnecessary treatment in patients unlikely to respond. KRAS mutation status is one marker used to predict response to inhibitors of epidermal growth factor receptor, but markers with broader applicability would be useful. Tol et al evaluated the prognostic and predictive role of prediagnostic levels of circulating tumor...